Applications

1394 – C1 Esterase Inhibitor

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New non-MBS item.

Service or technology in this application

C1 Esterase Inhibitor (C1-INH) concentrate is proposed for inclusion on the National Products and Services List (NPSL) for the management of patients with a confirmed diagnosis of Hereditary angioedema (HAE) Type I or II. Administration of human C1-INH to patients with HAE Type I or II replaces the missing or malfunctioning C1-INH protein resulting in relief from the symptoms of HAE.

Type: Therapeutic

Medical condition this application addresses

Hereditary angioedema (HAE) is an autosomal dominant disorder characterised by recurrent subcutaneous and submucosal oedema without urticaria. One or more of various peripheral or central areas can be affected during an acute HAE attack, with laryngeal swelling the most serious as it may be fatal.

Application documents

Consultation survey

PICO confirmation – Unratified draft protocol

PICO confirmation – Final protocol

Public summary document

Public summary document – Consumer friendly

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 11 - 12 December 2014
  • ESC meeting: 11 - 12 June 2015
  • MSAC meeting: 30 - 31 July 2015